Cargando…

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer

BACKGROUND: Current opinions on the benefits of adjuvant chemotherapy for stage II colon cancer are divided and reformative election of these patients is required. We examined whether the primary tumor location based on mismatch repair status and other risk factors could better inform the current gu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Lin, He, Wenzhuo, Yang, Qiong, Kong, Pengfei, Xie, Qiankun, Jiang, Chang, Zhang, Bei, Xia, Liang Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716799/ https://www.ncbi.nlm.nih.gov/pubmed/29228759 http://dx.doi.org/10.18632/oncotarget.21839

Ejemplares similares

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Extramedullary Hematopoiesis in Mismatch Repair Deficient Colon Cancer Patient on Adjuvant Chemotherapy
por: De Leo, Edward K, et al.
Publicado: (2021)

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer
por: Liu, Shousheng, et al.
Publicado: (2019)

Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study
por: Kang, Byung Woog, et al.
Publicado: (2021)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Adjuvant chemotherapy for stage II colon cancer: who really needs it
por: Yang, Yan, et al.
Publicado: (2018)

Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status
por: Kong, Pengfei, et al.
Publicado: (2019)

Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis
por: Kong, Pengfei, et al.
Publicado: (2017)

Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer
por: Yang, Lin, et al.
Publicado: (2018)

Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers
por: Yang, Lin, et al.
Publicado: (2017)

Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis
por: Tomasello, Gianluca, et al.
Publicado: (2022)

Impact of the 12-gene recurrence score in influencing adjuvant chemotherapy prescription in mismatch repair proficient stage II/III colonic carcinoma—a systematic review and meta-analysis
por: Davey, Matthew G., et al.
Publicado: (2023)

The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
por: Yunlong, Wu, et al.
Publicado: (2022)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

Clinical efficacy of adjuvant chemotherapy in the treatment of pT4 stage II colorectal cancer with defective mismatch repair status: A protocol for systematic review and meta-analysis
por: Huang, Li-Bin, et al.
Publicado: (2020)

Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
por: Jee, Sun Hee, et al.
Publicado: (2011)

Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer
por: Feng, Yang, et al.
Publicado: (2019)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
por: Kim, Min Ki, et al.
Publicado: (2018)

Circulating Tumour DNA Guided Adjuvant Chemotherapy Decision Making in Stage II Colon Cancer—A Clinical Vignette Study
por: To, Yat Hang, et al.
Publicado: (2023)

Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer
por: Hestetun, Kjersti Elvestad, et al.
Publicado: (2022)

Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
por: Zhang, Chunze, et al.
Publicado: (2022)

Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer
por: Lee, Kil-yong, et al.
Publicado: (2019)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

High Expression of CUL9 Is Prognostic and Predictive for Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer
por: Zheng, Peng, et al.
Publicado: (2022)

The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer
por: Chintamani, et al.
Publicado: (2007)

The impact of mismatch repair status and systemic inflammatory markers on radiological staging in colon cancer
por: Platt, James R, et al.
Publicado: (2023)

Adjuvant Chemotherapy and Tumor Sidedness in Stage II Colon Cancer: Analysis of the National Cancer Data Base
por: Mukkamalla, Shiva Kumar R., et al.
Publicado: (2020)

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review
por: To, Yat Hang, et al.
Publicado: (2023)

Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
por: Zhan, Yixiang, et al.
Publicado: (2023)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Brain metastases in newly diagnosed colorectal cancer: a population-based study
por: Yang, Lin, et al.
Publicado: (2018)

Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study
por: Liu, Lin-Lin, et al.
Publicado: (2022)

Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
por: Teufel, Andreas, et al.
Publicado: (2015)

The Prognostic Value of Deficient Mismatch Repair in Stage II–IVa Nasopharyngeal Carcinoma in the Era of IMRT
por: Chen, Fang-ming, et al.
Publicado: (2020)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
por: Lau, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5uchbus2plla0tgvnqqh88143k